- Details
- Alicia Morgans sits down with Thomas Powles to discuss the COSMIC-313 Phase III trial for clear cell renal cancer. Dr. Powles provides a comprehensive overview of the trial that explores a triplet of cabozantinib, ipilimumab, and nivolumab. The trial notably revealed a 25% reduction in the risk of progression, although overall survival signals were not yet evident. The data also revealed intriguin...
|
- Details
- Pedro Barata speaks with Alicia Morgans about his presentations focusing on genetic and germline testing in patients with advanced prostate cancer. Dr. Barata highlights a study that found more than two-thirds of the patient population had not been tested for homologous recombination repair (HRR) mutations, and another analysis of over 8,100 patients with metastatic castration-resistant prostate c...
|
- Details
- Andrea Necchi joins Alicia Morgans in a discussion on longer-term outcome data for non-muscle invasive bladder cancer patients without a carcinoma in-situ, cohort B in the KEYNOTE-057 study. The cohort B of the study focused on the patients without a CIS component and with only pTa or T1 papillary disease, high-risk disease, BCG-unresponsive disease. This is a difficult-to-treat patient population...
|
- Details
- Alicia Morgans and Oliver Sartor discuss the latest developments and changes in the advanced prostate cancer landscape. Dr. Sartor mentions that novel hormones are used as first-line treatment in most cases and that the controversy around treating first-line metastatic CRPC is no longer relevant. He believes the evolution is going to continue with the novel hormones going earlier in different sett...
|
- Details
- Andrea Necchi joins Alicia Morgans in a conversation about the FIDES-02 Study. This Phase 1b/2 study evaluated the efficacy and safety of derazantinib, a multi-TKI oral inhibitor that targets FGF receptor genomic alteration 1, 2, 3, and 4 genomic alterations, in patients with metastatic urothelial carcinoma. The focus is metastatic local advanced or metastatic patients with urothelial carcinoma of...
|
- Details
- Min Yuen Teo joins Sam Chang in a discussion on an ongoing Phase II clinical trial on neoadjuvant immune checkpoint inhibition, with both a combination of nivolumab and ipilimumab in patients with high grade invasive upper tract urothelial cancer who are cisplatin-ineligible. It was designed as a Phase II study with a two stage design. The study's primary endpoint was pathologic complete response;...
|
- Details
- Daniel Joyce joins Sam Chang to discuss oncologic outcomes, costs, and quality metrics for patients with both synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC). Upper tract urothelial carcinoma accounts for around 10% of all urothelial cancer cases that appear. Just around half of those will develop metastatic illness. This work's main objective was to determine what...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the ARASENS data and how it relates to whether patients with high-volume or low-volume metastatic castration-sensitive disease should be treated differently with systemic treatments. They explain that while historically, CHAARTED showed benefits in high-volume but not low-volume disease, STAMPEDE showed benefits for all patients regardless of volume. The rec...
|
- Details
- Neal Shores joins Alicia Morgans in conversation to discuss the RALU study. RALU is a retrospective analysis that sought to evaluate the safety and clinical outcomes of sequential radium-223/177Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study found that patients tolerated Lutetium-177 well, and PSA and alkaline phosphatase declines were observed....
|
- Details
- Scott Tagawa joins Alicia Morgans to discuss a randomized phase II study on a salvage anti-PSMA radioimmunotherapy targeting non-metastatic CRPC population. The study enrolled patients with high-risk non-metastatic CRPC, defined as a PSA doubling time of less than eight months or an absolute PSA of at least 20, low testosterone, and non-metastatic as defined by no evidence of metastasis on CT or M...
|
